Search Results - "Sappal, D"

577 Characterization of the cellular mechanism of action of the first in class investigational inhibitor of the Ubiquitin Activating Enzyme, MLN7243 by Milhollen, M, Sappal, D, Duffy, J, Hoar, K, Huck, J, Sha, P, Koenig, E, Hyer, M, Ciavarri, J, Bence, N

Get full text

561 Nonclinical characterization of the first in class investigational ubiquitin activating enzyme inhibitor MLN7243 in cellular and in vivo models of cancer in support of a phase I study by Milhollen, M, Hyer, M, Ciavarri, J, Traore, T, Sappal, D, Huck, J, Shi, J, Duffy, J, Gavin, J, Brownell, J, Yang, Y, Stringer, B, Ishii, Y, Koenig, E, Lublinsky, A, Griffin, R, Xia, C, Powe, J, Fleming, P, Bence, N

Get full text

Biological characterization of MLN944: a potent DNA binding agent by Sappal, Darshan S, McClendon, A Kathleen, Fleming, James A, Thoroddsen, Vala, Connolly, Kelly, Reimer, Corinne, Blackman, Ronald K, Bulawa, Christine E, Osheroff, Neil, Charlton, Peter, Rudolph-Owen, Laura A

“…MLN944 (XR5944) is a novel bis-phenazine that has demonstrated exceptional efficacy against a number of murine and human tumor models. The drug was reported…”
Get full text

The antiproliferative agent MLN944 preferentially inhibits transcription by Byers, Sarah A, Schafer, Blanca, Sappal, Darshan S, Brown, Jeffery, Price, David H

“…MLN944 is a novel compound currently being codeveloped by Millennium Pharmaceuticals and Xenova Ltd. as a cancer therapeutic and is in a phase I clinical trial…”
Get full text